JP2022537269A5 - - Google Patents
Info
- Publication number
- JP2022537269A5 JP2022537269A5 JP2021573213A JP2021573213A JP2022537269A5 JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5 JP 2021573213 A JP2021573213 A JP 2021573213A JP 2021573213 A JP2021573213 A JP 2021573213A JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144172A JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864960P | 2019-06-21 | 2019-06-21 | |
| US62/864,960 | 2019-06-21 | ||
| PCT/US2020/038669 WO2020257604A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Division JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022537269A JP2022537269A (ja) | 2022-08-25 |
| JP2022537269A5 true JP2022537269A5 (https=) | 2023-06-20 |
| JPWO2020257604A5 JPWO2020257604A5 (https=) | 2023-06-20 |
| JP7743314B2 JP7743314B2 (ja) | 2025-09-24 |
Family
ID=71842848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573213A Active JP7743314B2 (ja) | 2019-06-21 | 2020-06-19 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12091460B2 (https=) |
| EP (1) | EP3986934A1 (https=) |
| JP (2) | JP7743314B2 (https=) |
| KR (1) | KR20220024035A (https=) |
| CN (2) | CN118453851A (https=) |
| AU (1) | AU2020294790A1 (https=) |
| CA (1) | CA3140083A1 (https=) |
| IL (2) | IL288916B2 (https=) |
| MA (1) | MA56537A (https=) |
| MX (1) | MX2021015270A (https=) |
| WO (1) | WO2020257604A1 (https=) |
| ZA (1) | ZA202108895B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194596A (en) * | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| CN117729938A (zh) * | 2021-03-18 | 2024-03-19 | 纪念斯隆-凯特琳癌症中心 | 用于使用利用抗muc16×cd3多特异性抗体和vegf抑制剂的组合疗法治疗妇科癌症的方法 |
| KR20240159849A (ko) * | 2022-03-17 | 2024-11-06 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와 병용으로 재발성 상피 육종을 치료하는 방법 |
| EP4584300A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Multispecific constructs and uses thereof |
| WO2025082777A1 (en) * | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| CN106794264B (zh) * | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| JP6689836B2 (ja) * | 2014-10-16 | 2020-04-28 | ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ | 新規なイメージング組成物およびその使用 |
| CN107667120B (zh) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | 抗muc16抗体及其应用 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| EP3548515B1 (en) * | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| AU2017384126B2 (en) * | 2016-12-20 | 2025-01-23 | F. Hoffmann-La Roche Ag | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
-
2020
- 2020-06-19 IL IL288916A patent/IL288916B2/en unknown
- 2020-06-19 US US16/906,634 patent/US12091460B2/en active Active
- 2020-06-19 CA CA3140083A patent/CA3140083A1/en active Pending
- 2020-06-19 WO PCT/US2020/038669 patent/WO2020257604A1/en not_active Ceased
- 2020-06-19 CN CN202410406230.1A patent/CN118453851A/zh active Pending
- 2020-06-19 JP JP2021573213A patent/JP7743314B2/ja active Active
- 2020-06-19 MX MX2021015270A patent/MX2021015270A/es unknown
- 2020-06-19 CN CN202080045426.2A patent/CN113993547B/zh active Active
- 2020-06-19 AU AU2020294790A patent/AU2020294790A1/en active Pending
- 2020-06-19 KR KR1020217040895A patent/KR20220024035A/ko active Pending
- 2020-06-19 EP EP20747267.1A patent/EP3986934A1/en active Pending
- 2020-06-19 MA MA056537A patent/MA56537A/fr unknown
-
2021
- 2021-11-10 ZA ZA2021/08895A patent/ZA202108895B/en unknown
-
2024
- 2024-08-19 US US18/809,063 patent/US20250042999A1/en active Pending
- 2024-08-26 JP JP2024144172A patent/JP2024164188A/ja active Pending
-
2025
- 2025-10-09 IL IL323844A patent/IL323844A/en unknown